Changzhou Qianhong Biopharma Co Ltd (002550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Changzhou Qianhong Biopharma Co Ltd (002550) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥156.34 Million ≈ $22.88 Million USD) by net assets (CN¥2.76 Billion ≈ $403.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Changzhou Qianhong Biopharma Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Changzhou Qianhong Biopharma Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Changzhou Qianhong Biopharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Changzhou Qianhong Biopharma Co Ltd ranked by their cash flow conversion efficiency. Explore Changzhou Qianhong Biopharma Co Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metropolitan Kentjana Tbk
JK:MKPI
|
0.034x |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
VIA Technologies Inc
TW:2388
|
0.028x |
|
Asia Optical Co Inc
TW:3019
|
0.040x |
|
Ingles Markets Incorporated
NASDAQ:IMKTA
|
0.040x |
|
Jinhui Liquor Co Ltd
SHG:603919
|
-0.011x |
|
Kolon Industries Inc
KO:120110
|
0.025x |
|
Lotte Rental Co Ltd
KO:089860
|
-0.077x |
Annual Cash Flow Conversion Efficiency for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025. View Changzhou Qianhong Biopharma Co Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.77 Billion ≈ $404.78 Million |
CN¥361.36 Million ≈ $52.88 Million |
0.131x | -36.13% |
| 2024-12-31 | CN¥2.52 Billion ≈ $368.25 Million |
CN¥514.71 Million ≈ $75.32 Million |
0.205x | -5.13% |
| 2023-12-31 | CN¥2.47 Billion ≈ $362.01 Million |
CN¥533.33 Million ≈ $78.04 Million |
0.216x | +833.97% |
| 2022-12-31 | CN¥2.43 Billion ≈ $356.08 Million |
CN¥-71.47 Million ≈ $-10.46 Million |
-0.029x | -160.08% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.95 Million |
CN¥103.56 Million ≈ $15.15 Million |
0.049x | -68.17% |
| 2020-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
CN¥317.28 Million ≈ $46.43 Million |
0.154x | +121.81% |
| 2019-12-31 | CN¥2.33 Billion ≈ $341.34 Million |
CN¥161.55 Million ≈ $23.64 Million |
0.069x | +590.82% |
| 2018-12-31 | CN¥2.54 Billion ≈ $371.42 Million |
CN¥25.45 Million ≈ $3.72 Million |
0.010x | -72.22% |
| 2017-12-31 | CN¥2.45 Billion ≈ $358.94 Million |
CN¥88.52 Million ≈ $12.95 Million |
0.036x | -60.41% |
| 2016-12-31 | CN¥2.42 Billion ≈ $354.79 Million |
CN¥221.01 Million ≈ $32.34 Million |
0.091x | -27.00% |
| 2015-12-31 | CN¥2.29 Billion ≈ $335.75 Million |
CN¥286.50 Million ≈ $41.92 Million |
0.125x | +5.67% |
| 2014-12-31 | CN¥2.13 Billion ≈ $312.08 Million |
CN¥252.01 Million ≈ $36.88 Million |
0.118x | +45.10% |
| 2013-12-31 | CN¥1.97 Billion ≈ $288.35 Million |
CN¥160.47 Million ≈ $23.48 Million |
0.081x | -23.84% |
| 2012-12-31 | CN¥1.87 Billion ≈ $273.47 Million |
CN¥199.82 Million ≈ $29.24 Million |
0.107x | +28.62% |
| 2011-12-31 | CN¥1.77 Billion ≈ $258.44 Million |
CN¥146.82 Million ≈ $21.48 Million |
0.083x | -79.94% |
| 2010-12-31 | CN¥413.78 Million ≈ $60.55 Million |
CN¥171.51 Million ≈ $25.10 Million |
0.415x | +1109.63% |
| 2009-12-31 | CN¥243.68 Million ≈ $35.66 Million |
CN¥8.35 Million ≈ $1.22 Million |
0.034x | -86.26% |
| 2008-12-31 | CN¥217.99 Million ≈ $31.90 Million |
CN¥54.36 Million ≈ $7.95 Million |
0.249x | +46.60% |
| 2007-12-31 | CN¥211.61 Million ≈ $30.97 Million |
CN¥35.99 Million ≈ $5.27 Million |
0.170x | -- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more